
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
NBK CRISPR Activation Plasmid (h) | sc-401751-ACT | 20 µg | $397.00 |
BIK encodes NBK, a pro-apoptotic BH3-only member of the BCL-2 family that promotes mitochondrial outer membrane permeabilization by antagonizing anti-apoptotic proteins such as BCL-2, BCL-XL, and MCL1. NBK integrates intrinsic apoptotic signaling downstream of cellular stress pathways and contributes to caspase activation through regulation of cytochrome c release and apoptosome assembly. Its expression and post-translational control influence cell fate decisions in contexts including DNA damage responses, endoplasmic reticulum stress, and cytokine signaling. Dysregulated BIK/NBK activity has been linked to altered apoptosis sensitivity in multiple cancers and to broader disease-relevant processes involving epithelial homeostasis and immune cell survival.
NBK CRISPR Activation Plasmid (h) provides a targeted, non-destructive approach to upregulating endogenous BIK expression without altering the underlying DNA sequence.
NBK CRISPR Activation Plasmid (h) is a three-plasmid synergistic activation mediator (SAM) system engineered for highly efficient, site-specific transcriptional upregulation of the BIK locus in human cell lines. The system is built around a catalytically inactive Cas9 (dCas9) carrying two inactivating mutations (D10A and N863A) that eliminate nuclease activity while preserving DNA binding. This dCas9 is fused to VP64, a potent transcriptional activator, and is co-expressed with a blasticidin resistance gene for selection. The second plasmid encodes the MS2-p65-HSF1 fusion protein, a secondary activator complex that works in concert with dCas9-VP64, alongside a hygromycin resistance gene. The third plasmid encodes a target-specific 20 nt sgRNA fused to two MS2 RNA aptamers that recruit the MS2-p65-HSF1 complex to the activation site, accompanied by a puromycin resistance gene. The three plasmids are delivered at a 1:1:1 mass ratio for balanced expression of all system components.
Once assembled at the target locus, the SAM complex binds within approximately 200 bp upstream of the BIK transcriptional start site, where VP64, p65, and HSF1 act in concert to recruit transcriptional machinery and drive upregulation of endogenous NBK expression. Unlike nuclease-active Cas9, dCas9 does not introduce double-strand breaks or modify the genomic sequence, preserving the native BIK locus and enabling the study of NBK-dependent transcriptional responses at the endogenous locus, making it a valuable tool for functional studies, target gene identification, and the modeling of NBK pathway restoration in tumor cells with silenced or reduced BIK expression.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.